Knott David M Jr Raises Holdings in Liquidia Corporation $LQDA

Knott David M Jr lifted its position in Liquidia Corporation (NASDAQ:LQDA) by 19.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 107,783 shares of the company’s stock after purchasing an additional 17,783 shares during the quarter. Liquidia comprises about 1.0% of Knott David M Jr’s investment portfolio, making the stock its 20th biggest position. Knott David M Jr owned about 0.12% of Liquidia worth $2,451,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Liquidia by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after buying an additional 1,700 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Liquidia by 10.7% in the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after purchasing an additional 82,955 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Liquidia by 15.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after purchasing an additional 16,022 shares in the last quarter. Teacher Retirement System of Texas grew its stake in shares of Liquidia by 25.4% in the 2nd quarter. Teacher Retirement System of Texas now owns 17,185 shares of the company’s stock worth $214,000 after buying an additional 3,478 shares in the last quarter. Finally, Sigma Planning Corp increased its holdings in shares of Liquidia by 6.0% in the 2nd quarter. Sigma Planning Corp now owns 69,185 shares of the company’s stock worth $862,000 after buying an additional 3,910 shares during the last quarter. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Liquidia

In related news, insider Jason Adair sold 688 shares of Liquidia stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $41.65, for a total transaction of $28,655.20. Following the completion of the sale, the insider owned 211,169 shares in the company, valued at $8,795,188.85. This trade represents a 0.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel Russell Schundler sold 27,289 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $1,021,427.27. Following the completion of the sale, the general counsel directly owned 579,394 shares of the company’s stock, valued at approximately $21,686,717.42. This trade represents a 4.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 212,534 shares of company stock worth $7,964,719 over the last ninety days. 26.50% of the stock is currently owned by company insiders.

Liquidia Stock Performance

Shares of Liquidia stock opened at $36.03 on Friday. The stock’s fifty day moving average is $37.10 and its two-hundred day moving average is $30.89. The company has a market capitalization of $3.13 billion, a PE ratio of -43.41, a price-to-earnings-growth ratio of 0.60 and a beta of 0.52. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. Liquidia Corporation has a 52 week low of $11.26 and a 52 week high of $46.67.

Liquidia (NASDAQ:LQDA) last released its earnings results on Thursday, March 5th. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.18). The business had revenue of $92.02 million for the quarter. Liquidia had a negative return on equity of 237.79% and a negative net margin of 43.53%.The firm’s quarterly revenue was up 3072.4% compared to the same quarter last year. As a group, analysts expect that Liquidia Corporation will post -1.51 earnings per share for the current year.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Commercial momentum and profitability — Liquidia reported YUTREPIA net product sales of $90.1M in Q4 and $148.3M for 2025, achieved a second consecutive profitable quarter (Q4 net income $14.6M) and positive adjusted EBITDA, signaling rapid launch adoption and improving unit economics. GlobeNewswire Release
• Positive Sentiment: Balance sheet strength — the company ended 2025 with ~$190.7M in cash, improving liquidity and backing management’s plan to fund commercial expansion and clinical programs from operations. Quiver Quant Summary
• Positive Sentiment: Analyst upgrades and higher price targets — several firms raised ratings/targets after the quarter (HC Wainwright to $55, Needham to $54, BTIG to $50, Wells Fargo to $44), which supports further upside and likely contributed to intraday buying. Benzinga Analyst Roundup
• Neutral Sentiment: Mixed EPS headlines — Liquidia reported GAAP EPS of $0.15 for Q4. That missed some sell‑side consensus figures (~$0.33) but beat other estimates (Zacks cited $0.08), creating mixed investor interpretation of the results. Zacks Coverage
• Neutral Sentiment: Earnings materials and management commentary available — the slide deck and transcript provide color on commercial adoption, prescriber metrics and plans to fund L606 and other programs; useful for assessing sustainability of the launch. Earnings Presentation (Seeking Alpha)
• Negative Sentiment: Initial market reaction to the EPS headline — shares gapped down on the earnings headline before rebounding, showing sensitivity to EPS versus revenue/profitability nuance. That initial gap indicates headline risk if future quarters miss expectations. DefenseWorld: Gap Down
• Negative Sentiment: Insider and institutional sales — recent filings and summaries show notable insider sell activity and some large institutional reductions, which can weigh on sentiment if sustained. Fool: SEC Filing

Analyst Ratings Changes

A number of research analysts recently commented on LQDA shares. Wall Street Zen raised shares of Liquidia from a “hold” rating to a “buy” rating in a report on Saturday. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Liquidia in a research note on Thursday. Zacks Research downgraded Liquidia from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 27th. BTIG Research increased their price target on Liquidia from $49.00 to $50.00 and gave the company a “buy” rating in a report on Thursday. Finally, Jefferies Financial Group boosted their price objective on shares of Liquidia from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, January 13th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $42.00.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).